GBA Presents: THE BARE ESSENTIALS

The Loveshack apparently moved their earnings date.
It was supposed to be today, 3/29 now. Same day as RH.

I thought you owned this Stoney. You need to keep us up to date here a little better. I can't do everything.
 
Which definitely makes me the only person that has never heard of the guy.
Who is he? A hedge fund manager?



OMG Van-- It's a show about an American coaching a European soccer team and it's filled with good will and happy positive thoughts...
 
The Loveshack apparently moved their earnings date.
It was supposed to be today, 3/29 now. Same day as RH.

I thought you owned this Stoney. You need to keep us up to date here a little better. I can't do everything.



Don't remind me I completely F*ed this up-- stubborn. I still have. :banghead:
 
What's this about Van. A lot of people are buying this lately

Wayfair Inc. (W)- Up Up and away.

126.57+7.92(+6.68%)
As of 12:32PM EDT.

Description

Wayfair Inc. engages in the e-commerce business in the United States and internationally. The company provides approximately thirty-three million products for the home sector under various brands. It offers online selections of furniture, décor, housewares, and home improvement products through its sites, including Wayfair, Joss & Main, AllModern, Birch Lane, and Perigold brands. The company was founded in 2002 and is headquartered in Boston, Massachusetts.




 
Hi Ted- looks like a busted IPO

NeuroSense shares open at $4.55, IPO priced at $6.00 per unit 12/09/21 NRSN NeuroSense Therapeutics priced its initial public offering of 2M units, each consisting of one ordinary share and a warrant representing the right to purchase one ordinary share with an exercise price of $6.00 per share, at an initial public offering price of $6.00 per unit. NeuroSense's ordinary shares and warrants are trading on the Nasdaq Capital Market under the ticker symbols "NRSN" and "NRSNW," respectively.

NeuroSense initiated with a Buy at Maxim 01/07 NRSN Maxim analyst Naz Rahman initiated coverage of NeuroSense with a Buy rating and $7.00 price target. The company's lead asset PrimeC, which is being developed to treat amyotrophic lateral sclerosis, demonstrated positive results in a pre-clinical Zebrafish model in which it increased fish swim distance and velocity, the analyst tells investors in a research note. Rahman adds that he is positive on PrimeC's mechanism of action and potential as an approved therapy for indications that current treatments do not address.

:D Any bio that only needs to increase swim distance in Zebra fish has a low bar to hurdle!
If i worked at this company I would of sprinkled in some protein powder into the fish tank and energy boosting herbs when no one was looking.

vol outrageous I don't get it... feakin' Zebra fish....

Vol 105,MILLION
Avg. Volume 610,845

I would stay far away. This will be $4.00 soon which seems the fair price.

6.79+5.23(+335.26%)
As of 12:13PM EDT.




I'm a little worried about Ted. I warned him too
 
Back
Top